CCID Consulting, a firm affiliated with a think tank under the Ministry of Industry and Information Technology, recently released a list of China's top 100 biomedical industrial parks in 2022. Four industrial parks from Changsha City made the list. They are the Changsha High-tech Industrial Development Zone, the Liuyang Economic and Technological Development Zone, the Changsha Economic and Technological Development Zone and the Wangcheng Economic and Technological Development Zone, ranking 17th, 37th, 50th and 90th respectively.

The biomedical (gene technology) industrial chain is one of the 22 industrial chains that Changsha focuses on developing. It ranked first among the 22 industrial chains, in terms of the total number of listed companies, the total market value, the maximum market value, the number of listed enterprises each with a market value of over 10 billion yuan, and the number of enterprises to be listed.

In recent years, the Changsha High-tech Industrial Development Zone has vigorously developed the biomedical industrial cluster or chain. It has made continuous efforts in the subfields such as Chinese patent medicines, in vitro diagnosis (IVD), gene technology and medical devices, and embarked on a high-end and differentiated development path. In 2021, the zone's biomedical revenue reached 39.5 billion yuan, an increase of 19.7%.

The Liuyang Economic and Technological Development Zone is founded based on the biomedical industry. The industry has made the zone a national innovative drug incubation base and the first national biological industry base in central and western China. It has maintained a rapid growth for many years.

The zone has gathered more than 180 biomedical enterprises such as Jiudian Pharmaceutical, ER-KANG Pharmaceutical and Warrant Pharmaceutical. Its industrial chain is complete, involving various sectors such as biomedicine and medical devices.

Source: en.changsha.gov.cn